# A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

> **NCT05355701** · PHASE1 · RECRUITING · sponsor: **Pfizer** · enrollment: 267 (estimated)

## Conditions studied

- Melanoma
- Non-Small-Cell Lung Cancer
- Thyroid Cancer
- Glioma
- Advanced Colorectal Cancer (Part 1)

## Interventions

- **DRUG:** PF-07799933
- **DRUG:** binimetinib
- **BIOLOGICAL:** cetuximab
- **DRUG:** midazolam
- **DRUG:** fluorouracil
- **DRUG:** leucovorin
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT05355701
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-05
- **Primary completion:** 2029-02-02
- **Final completion:** 2030-08-06
- **Target enrollment:** 267 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05355701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05355701, "A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05355701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*